BSIO Annual Conference 2024

BSIO (British Society for Integrative Oncology) is the leading professional organisation for integrative oncology in the UK. Our goal is to promote the integration of evidence-informed conventional, nutritional, lifestyle and complementary medicine to improve the lives of people affected by cancer.

The 2024 Annual Conference ‘Integrative oncology across the age spectrum’ offers a unique opportunity to hear from a wide range of integrative oncology experts as they discuss the challenges of supporting their patients from early years through to older adults.

During the day, you’ll hear first hand from an oncology team, whose combined skills and knowledge have positively impacted the young patients and families in their care. We will also explore the integrative oncology solutions to living with and beyond cancer in teenagers and young adults.  The conference will also address the challenges of supporting men through their cancer diagnosis, and how best to engage this group in integrative oncology as well as examining the impact of cancer on sexual intimacy in women; an area that is often overlooked.  There will also be a session dedicated to the integrative oncology approaches to support the needs of older people, before the day ends with a Panel Q&A and closing remarks.  With an incredible line-up of international and UK experts, we are sure the day will offer valuable insights for any professional working in cancer support.

Please view the outline agenda and register to join us at the conference on Saturday 20th April using the link below:
https://tinyurl.com/8m54frev
Don’t miss out on the early bird rate with an additional 10% off the ticket price using the code bopa10 (for non-BSIO members).

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article